Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birch pollen extract - Stallergenes Greer plc

Next Previous
Drug Profile

Birch pollen extract - Stallergenes Greer plc

Alternative Names: Bet v 1; Bet v 1a; Oralair Bet V 1 recombinant allergen; Oralair Birch; rBet v 1; Staller (Birch); Staloral Birch; STALORAL® Birch 300 IR

Latest Information Update: 05 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Endo, Inc.; Stallergenes Greer plc; Stallergenes SA
  • Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 30 Oct 2025 Efficacy and adverse events data from a phase III YOBI trial in Seasonal allergic rhinitis released by Stallergenes Greer
  • 06 Aug 2025 Stallergenes Greer completes a phase III trial in Seasonal allergic rhinitis in Finland, Sweden, France, Germany, Lithuania, Hungary, Latvia, Poland, Romania, Bulgaria, Slovakia and Austria (Sublingual) (In children, In adolescents) (NCT05668390)
  • 20 Jun 2024 Phase-III development for Seasonal allergic rhinitis is ongoing in Denmark, Czech Republic, Estonia, Finland, France, Germany, Poland, Sweden, Latvia, Lithuania, Slovakia (Sublingual)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top